Detalles de la búsqueda
1.
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.
Breast Cancer Res Treat
; 192(1): 153-161, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35112166
2.
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Breast Cancer Res Treat
; 193(3): 555-564, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35230585
3.
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
N Engl J Med
; 379(8): 753-763, 2018 08 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30110579
4.
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
Oncologist
; 25(3): e439-e450, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162822
5.
Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
Breast Cancer Res Treat
; 180(1): 219-226, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31975315
6.
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(1): 88-99, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30509771
7.
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Lancet
; 387(10030): 1837-46, 2016 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-26970723
8.
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Lancet
; 387(10021): 849-56, 2016 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-26686957
9.
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Lancet
; 387(10021): 857-65, 2016 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-26686960
10.
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Breast Cancer Res Treat
; 193(3): 565, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35507135
11.
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40.
Ann Surg Oncol
; 24(7): 1853-1860, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27864694
12.
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Lancet Oncol
; 16(9): 1037-1048, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26272770
13.
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
N Engl J Med
; 366(4): 310-20, 2012 Jan 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-22276821
14.
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Lancet Oncol
; 14(12): 1183-92, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24095300
15.
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
Clin Cancer Res
; 30(9): 1984-1991, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38376912
16.
HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease.
Breast Cancer Res
; 15(2): R24, 2013 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-23497539
17.
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
N Engl J Med
; 362(22): 2053-65, 2010 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-20519679
18.
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.
Lancet Oncol
; 13(7): 734-42, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22704583
19.
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease.
J Clin Oncol
; 41(8): 1501-1510, 2023 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36881998
20.
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer.
J Clin Oncol
; 41(9): 1638-1645, 2023 03 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36921335